Skip to main content

Table 3 Statistical analysis of clinicopathological variables related to SPAG5 and NuMA mRNA expressions

From: Investigation of the SPAG5 gene expression and amplification related to the NuMA mRNA levels in breast ductal carcinoma

 

N (%)

t

SSig. (2-tailed)

Std. Error

95% CI

Lower

Upper

SPAG5

Age

< 50 years

16(40)

− 1.05

0.29

1.19

− 3.67

1.15

> 50 years

24(60)

Grade

I and II

30(75)

− 0.97

0.33

1.31

− 3.94

1.37

III

10(25)

LN

Positive

18(45.5)

0.77

0.44

1.18

− 1.47

3.31

Negative

22(55.5

FH

Positive

13(32.5)

0.78

0.43

1.25

− 1.55

3.53

Negative

27(67.5)

ER

Positive

35(87.5)

− 0.19

0.84

1.79

− 3.98

3.27

Negative

5(12.5)

PR

Positive

33(82.5)

− 0.02

0.98

1.56

− 3.20

3.12

Negative

7(17.5)

HER2

Positive

7(17.5)

− 0.02

0.98

1.56

− 3.20

3.12

Negative

33(82.5)

NUMA

Age

< 50 years

16(40)

0.89

0.37

0.79

− 0.90

2.32

> 50 years

24(60)

Grade

I and II

30(75)

− 1.91

0.06

0.84

− 3.32

0.09

III

10(25)

LN

Positive

18(45.5)

− 1.0

0.32

0.78

− 2.37

0.79

Negative

22(55.5

FH

Positive

13(32.5)

− 1.93

0.06

0.80

− 3.18

0.06

Negative

27(67.5)

ER

Positive

35(87.5)

− 2.90

0.006

1.07

− 5.32

− 0.95

Negative

5(12.5)

PR

Positive

33(82.5)

− 0.79

0.43

1.03

− 2.90

1.26

Negative

7(17.5)

HER2

Positive

7(17.5)

− 0.79

0.43

1.03

− 2.90

1.26

Negative

33(82.5)

  1. Independent sample t test was applied to compare the SPAG5 and NuMA gene expression levels according to clinicopathological features. Normal distribution of variables and equality of variances were checked by Kolmogorov-Smirnov and Levene’s test, respectively. The significance level was selected at 0.05.
  2. N number, t t test, sig significance (p value), Std standard, CI confidence intervals, SPAG5 sperm-associated antigen, NuMA nuclear mitotic apparatus protein, LN lymph node involvement, FH family history, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2